Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus CYCLAPEN W.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus CYCLAPEN W.
BACTOCILL vs CYCLAPEN-W
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic